Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (Nasdaq: MNPR) said the FDA authorized it to initiate a rolling NDA submission for ALXN1840 (tiomolibdate choline, TMC) for Wilson disease. The company submitted the first completed NDA sections. ALXN1840 has Fast Track and Orphan Drug designations and received Rare Pediatric Disease status in June 2026.

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.

Worthington Steel Inc (WS) reported Q1 2027 earnings with $954M net sales, up 9% YoY, and adjusted EBITDA of $111M. The Kloeckner acquisition expanded operations but resulted in a net loss of $7M due to higher interest and purchase accounting impacts. Automotive and agriculture shipments grew, while energy and construction declined. Net debt stands at $1.9B. Management expects synergy benefits post-integration.

Tesco raised its full-year profit guidance after reporting a 6.5% rise in first-half adjusted operating profit to £1.78 billion. The company now expects £3.15 billion to £3.30 billion in adjusted operating profit. Sales rose 2.0% to £33.8 billion, and earnings per share increased 12.2% to 17.3p. Tesco increased its share buyback and capital expenditure guidance, with online sales growing 8%.

Tesco Plc reported a 11.5% increase in H1 profit before tax to £1.455 billion, with revenue up 3.7% to £37.353 billion. EPS rose 17.4% to 16.7 pence. The company raised its FY27 profit outlook to £3.15-3.30 billion and increased its share buyback program to £950 million. An interim dividend of 5.05 pence per share was announced.

Samsung 005930 forecasted a 783% year-over-year increase in quarterly operating profit to $80 billion, driven by AI memory demand. Revenue is expected to rise 126.6% to 195 trillion won. Despite strong earnings, shares slipped 0.2% in early trading, reflecting investor caution about the sustainability of the boom.